Dec 14 2021 |
et al., medRxiv, doi:10.1101/2021.12.09.21267566 | Oral antiviral clevudine compared with placebo in Korean COVID-19 patients with moderate severity |
| 744% worse recovery (p=0.16) and 27% improved viral clearance (p=0.56). RCT 61 moderate COVID-19 patients in Korea showing no significant difference in viral clearance or clinical outcomes with clevudine compared to placebo. | ||
Jul 8 2021 |
et al., NCT04891302 | A Double Blind, Randomized, Placebo-controlled, Multi-center, Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Mild and Moderate COVID-19 |
| 104 patient clevudine late treatment RCT with results not reported over 3 years after completion. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.